SBI-581
| 产品介绍 | SBI-581是一种口服有效的选择性的丝氨酸苏氨酸激酶 TAO3 抑制剂,IC50 值为 42 nM。SBI-581 促进 RAB11 阳性囊泡中 TKS5α 的积累。SBI-581 抑制侵袭性伪足形成。SBI-581 在小鼠腹腔注射后的药代动力学较为合理。SBI-581 具有抗肿瘤活性。 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | SBI-581 is an orally active and potent selective serine-threonine kinase TAO3 inhibitor, with an IC50 of 42 nM. SBI-581 promotes TKS5α accumulation at RAB11-positive vesicles. SBI-581 inhibits invadopodia formation. SBI-581 shows reasonable pharmacokinetics in mice using IP injection. SBI-581 shows antitumor activity. | ||||||||||||||||
| 体外研究 |
SBI-581 shows moderate selectivity (> 5-10x) against the majority of a broad panel of kinases. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 体内研究 |
SBI-581 (10 mg/kg, IP, once) displays reasonable pharmacokinetics (t1/2=1.5 hr; AUC= 1202 hr*ng/mL; Cmax= ~2 μM). 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 体内研究 |
SBI-581 (10 mg/kg, IP, once) displays reasonable pharmacokinetics (t1/2=1.5 hr; AUC= 1202 hr*ng/mL; Cmax= ~2 μM). 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| 溶解性数据 |
In Vitro:
DMSO : 50 mg/mL (130.40 mM; ultrasonic and warming and heat to 60°C) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 参考文献 |

浙公网安备 33010802013016号